Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 1, 2010, Pages 53-62

  Bouyssou, T ^a   Casarosa, P ^a   Naline, E ^b   Pestel, S ^a   Konetzki, I ^a   Devillier, P ^b   Schnapp, Andreas ^a  

^a B Ingelheim Pharma GmbH/Co KG   (Germany)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; GLUCOSE; ISOPRENALINE; LACTIC ACID; OLODATEROL; POTASSIUM; SALMETEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS; DOG; DRUG MECHANISM; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; GUINEA PIG; HEART RATE; IN VITRO STUDY; LACTATE BLOOD LEVEL; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; BENZOXAZINES; BRONCHI; BRONCHOCONSTRICTION; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DELAYED-ACTION PREPARATIONS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUINEA PIGS; HUMANS; MALE; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2; TIME FACTORS; TRANSFECTION;

EID: 77953799906     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167007     Document Type: Article

References (28)

1. Barnes PJ (2004) The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 117 (Suppl 12A):24S-32S.
2. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al. (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143-178.
3. Bender BG (2002) Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 109:S554-S559.
4. Braman SS (2006) The global burden of asthma. Chest 130:4S-12S.
5. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, and Pieper M (2009) Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 330:660-668.
6. Casarosa P, Waldhoer M, LiWang PJ, Vischer HF, Kledal T, Timmerman H, Schwartz TW, Smit MJ, and Leurs R (2005) CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor. J Biol Chem 280:3275-3285.
7. Cazzola M and Matera MG (2008) Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155:291-299.
8. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Dalby R, Spallek M, and Voshaar T (2004) A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 283:1-9.
10. Gold PM (2009) The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care 54:1040-1049.
11. Greaves P (1998) Patterns of drug-induced cardiovascular pathology in the beagle dog: relevance for humans. Exp Toxicol Pathol 50:283-293.
12. Greaves P (2000) Patterns of cardiovascular pathology induced by diverse cardioactive drugs. Toxicol Lett 112-113:547-552.
13. Guerra S (2009) Asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 9:409-416.
14. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, and Vestbo J (2009) Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 10:59.
15. Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186-192.
16. Larj MJ and Bleecker ER (2002) Effects of β2-agonists on airway tone and bronchial responsiveness. J Allergy Clin Immunol 110:S304-S312.
17. Lipworth BJ and Grove A (1997) Evaluation of partial β-adrenoceptor agonist activity. Br J Clin Pharmacol 43:9-14. (Pubitemid 27060263)
18. Mak JC, Grandordy B, and Barnes PJ (1994) High affinity [3H]formoterol binding sites in lung: characterization and autoradiographic mapping. Eur J Pharmacol 269:35-41. (Pubitemid 24288292)
19. Meng YY, Leung KM, Berkbigler D, Halbert RJ, and Legorreta AP (1999) Compliance with U.S. asthma management guidelines and specialty care: a regional variation or national concern? J Eval Clin Pract 5:213-221.
20. Naline E, Zhang Y, Qian Y, Mairon N, Anderson GP, Grandordy B, and Advenier C (1994) Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 7:914-920.
21. Naline E, Trifilieff A, Fairhurst RA, Advenier C, and Molimard M (2007) Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi. Eur Respir J 29:575-581.
22. O'Byrne P, Van der Linde J, Cockroft DW, Brannan JD, Fitzgerald M, Watson RM, Milot J, Davis B, O'Connor M, Hart L, et al. (2009) Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma. J Allergy Clin Immunol 124:1217-1221.
23. Pauwels RA and Rabe KF (2004) Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364:613-620.
24. Sovani MP, Whale CI, and Tattersfield AE (2004) A benefit-risk assessment of inhaled long-acting β2-agonists in the management of obstructive pulmonary disease. Drug Saf 27:689-715.
25. Tamura G and Ohta K (2007) Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 101:1895-1902.
26. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, and UPLIFT Study Investigators (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease 7. N Engl J Med 359:1543-1554.
27. 2- agonist, is effective in COPD patients. Am J Respir Crit Care Med 179:A6183.
28. Walland A, Palluk R, Burkard S, and Hammer R (1997) Compensation of muscarinic bronchial effects of talsaclidine by concomitant sympathetic activation in guinea pigs. Eur J Pharmacol 330:213-219.